J Neurol Surg B Skull Base 2022; 83(02): 210-214
DOI: 10.1055/s-0040-1718766
Original Article

The Efficacy of Adjuvant Chloroquine for Glioblastoma: A Meta-Analysis of Randomized Controlled Studies

Hong Wei
1   Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Liaoning, China
Zhenfu Jiang
2   Department of Neurosurgery, The Second Hospital of Dalian Medical University, Liaoning, China
› Author Affiliations


Introduction The efficacy of adjuvant chloroquine for glioblastoma remains controversial. We conduct a systematic review and meta-analysis to explore the influence of adjuvant chloroquine on treatment efficacy for recurrent glioblastoma.

Methods We search PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through January 2020 for randomized controlled trials (RCTs) assessing the efficacy of adjuvant chloroquine for glioblastoma. This meta-analysis is performed using the random-effect model.

Results Three RCTs are included in the meta-analysis. Overall, compared with control group for glioblastoma, adjuvant chloroquine is associated with significantly reduced mortality (risk ratio [RR] = 0.59; 95% confidence interval [CI] = 0.47–0.72; p < 0.00001), improved remission (RR = 11.53; 95% CI = 1.53–86.57; p = 0.02), and prolonged survival time (Std.MD = 11.53; 95% CI = 1.53–86.57; p = 0.02), but has no substantial effect on recurrence (RR = 0.42; 95% CI = 0.12–1.49; p = 0.18).

Conclusion Adjuvant chloroquine may provide additional benefits for the treatment of glioblastoma.

Publication History

Received: 09 March 2020

Accepted: 19 August 2020

Article published online:
11 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010; 67 (03) 279-283
  • 2 Wang J, Shen F, Yao Y, Wang LL, Zhu Y, Hu J. Adoptive cell therapy: a novel and potential immunotherapy for glioblastoma. Front Oncol 2020; 10: 59
  • 3 van der Louw EJTM, Olieman JF, van den Bemt PMLA. et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study. Ther Adv Med Oncol 2019; 11: 1758835919853958
  • 4 Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144 (05) 337-343
  • 5 Ji X, Zhu H, Dai X. et al. Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme. Cancer Biomark 2019; 25 (03) 275-290
  • 6 Dong Q, Li Q, Wang M. et al. Elevated CD44 expression predicts poor prognosis in patients with low-grade glioma. Oncol Lett 2019; 18 (04) 3698-3704
  • 7 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
  • 8 Gilbert MR, Wang M, Aldape KD. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31 (32) 4085-4091
  • 9 Souhami L, Seiferheld W, Brachman D. et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60 (03) 853-860
  • 10 Grossman SA, Batara JF. Current Management of Glioblastoma Multiforme, Seminars in Oncology. Elsevier; 2004: 635-644
  • 11 Briceño E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003; 14 (02) e3
  • 12 Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 2003; 3 (11) 722-727
  • 13 Reyes S, Herrera LA, Ostrosky P, Sotelo J. Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery 2001; 49 (04) 969-973
  • 14 Jia-ming C. Clinical observation of chloroquine treatment for glioma. Ann Intern Med 2011; 17 (12) 1900-1901
  • 15 Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
  • 16 G. HigginsJPT, Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011], The Cochrane collaboration 2011
  • 17 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (01) 1-12
  • 18 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135 (11) 982-989
  • 19 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21 (11) 1539-1558
  • 20 Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev 2015; 29 (12) 1203-1217
  • 21 Wang J, Cazzato E, Ladewig E. et al. Clonal evolution of glioblastoma under therapy. Nat Genet 2016; 48 (07) 768-776
  • 22 Qian Z, Ren L, Wu D. et al. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. Int J Cancer 2017; 140 (12) 2792-2804
  • 23 Wasserfallen JB, Ostermann S, Pica A. et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer 2004; 101 (09) 2098-2105
  • 24 Lopez-Gonzalez MA, Sotelo J. Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg Neurol 2000; 53 (02) 157-162
  • 25 Wong ET, Hess KR, Gleason MJ. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17 (08) 2572-2578
  • 26 Duerinck J, Du Four S, Bouttens F. et al. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. J Neurooncol 2018; 136 (01) 115-125
  • 27 Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 1994; 54 (11) 2959-2963
  • 28 Pozzi D, Zompetta C, Faggioni A. et al. Early events of fusion between Epstein Barr virus and human lymphoblastoid cells (Raji) detected by R18 fluorescence dequenching measurements. Membr Biochem 1990; 9 (04) 239-251
  • 29 Inaba M, Maruyama E. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine. Cancer Res 1988; 48 (08) 2064-2067